adrenomed-logo (002).jpg
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
April 10, 2024 08:00 ET | Adrenomed AG
With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths...
adrenomed-logo (002).jpg
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
September 08, 2023 04:00 ET | Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...